Cancer Research UK
- Academic, tech transfer
- Biotech or pharma, therapeutic R&D
- Investor (buy-side or sell-side research)
Cancer Research Horizons (CRH) is the innovation engine of Cancer Research UK (CRUK), the world’s largest charitable funder of cancer research. We operate as an oncology-focused drug discovery, development, and IP commercialisation organisation, fast-tracking scientific breakthroughs for patient benefit. With exclusive rights to IP from CRUK’s $500m annual R&D spend, we unite cutting-edge science, top investigators, and IP across the CRUK Network.
CRH has helped form over 80 startups and brought 14 cancer drugs to market, enabling more than 6 million treatment courses for patients worldwide. CRH offers unique access to CRUK’s science portfolio and serves as a gateway for partners to connect with cancer expertise, R&D capabilities, and infrastructure. We offer licensing, collaborations, and startup formation/investment. With integrated drug discovery and early clinical development, we drive innovations from target discovery to clinical PoC through alliances and partnerships.

